It belongs to the same structural family as BPC-157, the widely researched 15-amino-acid compound, with the arginate salt modification studied for its potential to hold up better in the digestive environment
Discover how it affects weight loss, side effects, and your health when taking this GLP-1 medication
MET-097s promising Phase 1 results suggest that it could address several unmet needs in this space, particularly by offering: Once-Monthly Dosing: Unlike many other GLP-1 receptor agonists that require weekly or even daily administration, MET-097s extended half-life could enable monthly or less frequent dosing, significantly reducing the burden of frequent injections on patients
Start with balanced meals that include protein, fiber, and healthy fats
For many, diet and exercise may not suffice
Conditions that suppress the immune system, such as HIV/AIDS or certain cancers, can increase this risk